Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
3.300
-0.020 (-0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
3.530
+0.230 (6.97%)
After-hours: Apr 28, 2026, 6:32 PM EDT
Biodexa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
2.14M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBDRX News
- 26 days ago - Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - GlobeNewsWire
- 4 weeks ago - Preliminary Results for the Year Ended 31 December 2025 - GlobeNewsWire
- 5 weeks ago - Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - GlobeNewsWire
- 5 weeks ago - ADR Ratio Change - GlobeNewsWire
- 7 weeks ago - Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - GlobeNewsWire
- 2 months ago - Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Accesswire
- 2 months ago - Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - GlobeNewsWire
- 4 months ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire